vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and MediaAlpha, Inc. (MAX). Click either name above to swap in a different company.

MediaAlpha, Inc. is the larger business by last-quarter revenue ($310.0M vs $196.0M, roughly 1.6× Axsome Therapeutics, Inc.). MediaAlpha, Inc. runs the higher net margin — 4.5% vs -14.6%, a 19.1% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 17.3%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 31.9%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Alpha Group Co., Ltd. is a Chinese multinational conglomerate with animation, toy, mass media asset and entertainment company headquartered created by Cai Dongqing in 1993. In 2016, it changed its name from Alpha Animation. The company has a Chinese webcomics site, U17, and also an American film company, Alpha Pictures, and has announced the creation of an animation division also based in the United States.

AXSM vs MAX — Head-to-Head

Bigger by revenue
MAX
MAX
1.6× larger
MAX
$310.0M
$196.0M
AXSM
Growing faster (revenue YoY)
AXSM
AXSM
+47.7% gap
AXSM
65.0%
17.3%
MAX
Higher net margin
MAX
MAX
19.1% more per $
MAX
4.5%
-14.6%
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
31.9%
MAX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AXSM
AXSM
MAX
MAX
Revenue
$196.0M
$310.0M
Net Profit
$-28.6M
$14.0M
Gross Margin
15.1%
Operating Margin
-13.8%
7.2%
Net Margin
-14.6%
4.5%
Revenue YoY
65.0%
17.3%
Net Profit YoY
61.9%
701.8%
EPS (diluted)
$-0.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
MAX
MAX
Q1 26
$310.0M
Q4 25
$196.0M
$291.2M
Q3 25
$171.0M
$306.5M
Q2 25
$150.0M
$251.6M
Q1 25
$121.5M
$264.3M
Q4 24
$118.8M
$300.6M
Q3 24
$104.8M
$259.1M
Q2 24
$87.2M
$178.3M
Net Profit
AXSM
AXSM
MAX
MAX
Q1 26
$14.0M
Q4 25
$-28.6M
$31.4M
Q3 25
$-47.2M
$14.9M
Q2 25
$-48.0M
$-18.7M
Q1 25
$-59.4M
$-1.9M
Q4 24
$-74.9M
$4.6M
Q3 24
$-64.6M
$9.5M
Q2 24
$-79.3M
$3.6M
Gross Margin
AXSM
AXSM
MAX
MAX
Q1 26
15.1%
Q4 25
15.4%
Q3 25
14.2%
Q2 25
15.0%
Q1 25
15.8%
Q4 24
16.3%
Q3 24
15.1%
Q2 24
17.8%
Operating Margin
AXSM
AXSM
MAX
MAX
Q1 26
7.2%
Q4 25
-13.8%
7.7%
Q3 25
-27.0%
6.4%
Q2 25
-24.5%
-8.0%
Q1 25
-46.9%
0.0%
Q4 24
-61.1%
6.1%
Q3 24
-59.8%
6.0%
Q2 24
-89.5%
3.6%
Net Margin
AXSM
AXSM
MAX
MAX
Q1 26
4.5%
Q4 25
-14.6%
10.8%
Q3 25
-27.6%
4.9%
Q2 25
-32.0%
-7.4%
Q1 25
-48.9%
-0.7%
Q4 24
-63.1%
1.5%
Q3 24
-61.7%
3.7%
Q2 24
-91.0%
2.0%
EPS (diluted)
AXSM
AXSM
MAX
MAX
Q1 26
Q4 25
$-0.55
$0.50
Q3 25
$-0.94
$0.26
Q2 25
$-0.97
$-0.33
Q1 25
$-1.22
$-0.04
Q4 24
$-1.54
$0.09
Q3 24
$-1.34
$0.17
Q2 24
$-1.67
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
MAX
MAX
Cash + ST InvestmentsLiquidity on hand
$322.9M
$26.1M
Total DebtLower is stronger
$163.5M
Stockholders' EquityBook value
$88.3M
Total Assets
$689.8M
$367.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
MAX
MAX
Q1 26
$26.1M
Q4 25
$322.9M
$46.9M
Q3 25
$325.3M
$38.8M
Q2 25
$303.0M
$85.4M
Q1 25
$300.9M
$63.6M
Q4 24
$315.4M
$43.3M
Q3 24
$327.3M
$32.3M
Q2 24
$315.7M
$28.7M
Total Debt
AXSM
AXSM
MAX
MAX
Q1 26
$163.5M
Q4 25
$153.4M
Q3 25
$155.7M
Q2 25
$158.0M
Q1 25
$160.2M
Q4 24
$162.4M
Q3 24
$164.7M
Q2 24
$166.9M
Stockholders' Equity
AXSM
AXSM
MAX
MAX
Q1 26
Q4 25
$88.3M
$4.2M
Q3 25
$73.7M
$-29.8M
Q2 25
$73.1M
$-3.8M
Q1 25
$53.2M
$7.9M
Q4 24
$57.0M
$2.4M
Q3 24
$92.9M
$-8.4M
Q2 24
$102.9M
$-24.4M
Total Assets
AXSM
AXSM
MAX
MAX
Q1 26
$367.7M
Q4 25
$689.8M
$383.8M
Q3 25
$669.3M
$266.2M
Q2 25
$639.8M
$249.4M
Q1 25
$596.7M
$240.0M
Q4 24
$568.5M
$262.4M
Q3 24
$561.5M
$236.1M
Q2 24
$548.2M
$198.2M
Debt / Equity
AXSM
AXSM
MAX
MAX
Q1 26
Q4 25
36.88×
Q3 25
Q2 25
Q1 25
20.23×
Q4 24
68.31×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
MAX
MAX
Operating Cash FlowLast quarter
$-18.7M
Free Cash FlowOCF − Capex
$-18.7M
FCF MarginFCF / Revenue
-9.6%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
MAX
MAX
Q1 26
Q4 25
$-18.7M
$-7.4M
Q3 25
$1.0M
$23.6M
Q2 25
$-32.4M
$25.7M
Q1 25
$-43.4M
$23.7M
Q4 24
$-26.2M
$14.5M
Q3 24
$-18.6M
$8.1M
Q2 24
$-30.1M
$21.6M
Free Cash Flow
AXSM
AXSM
MAX
MAX
Q1 26
Q4 25
$-18.7M
$-7.5M
Q3 25
$988.0K
$23.6M
Q2 25
$-32.4M
$25.5M
Q1 25
$-43.7M
$23.6M
Q4 24
$-26.2M
$14.5M
Q3 24
$-18.7M
$8.0M
Q2 24
$-30.2M
$21.5M
FCF Margin
AXSM
AXSM
MAX
MAX
Q1 26
Q4 25
-9.6%
-2.6%
Q3 25
0.6%
7.7%
Q2 25
-21.6%
10.2%
Q1 25
-36.0%
8.9%
Q4 24
-22.1%
4.8%
Q3 24
-17.9%
3.1%
Q2 24
-34.6%
12.0%
Capex Intensity
AXSM
AXSM
MAX
MAX
Q1 26
Q4 25
0.0%
0.0%
Q3 25
0.0%
0.0%
Q2 25
0.0%
0.1%
Q1 25
0.3%
0.0%
Q4 24
0.0%
0.0%
Q3 24
0.1%
0.0%
Q2 24
0.1%
0.1%
Cash Conversion
AXSM
AXSM
MAX
MAX
Q1 26
Q4 25
-0.24×
Q3 25
1.58×
Q2 25
Q1 25
Q4 24
3.13×
Q3 24
0.85×
Q2 24
5.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons